SNS-314

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H15ClN6OS2
Molecular Weight	430.934
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=CC(NC(=O)NC2=NC=C(CCNC3=C4SC=CC4=NC=N3)S2)=C1

InChI

InChIKey=FAYAUAZLLLJJGH-UHFFFAOYSA-N

InChI=1S/C18H15ClN6OS2/c19-11-2-1-3-12(8-11)24-17(26)25-18-21-9-13(28-18)4-6-20-16-15-14(5-7-27-15)22-10-23-16/h1-3,5,7-10H,4,6H2,(H,20,22,23)(H2,21,24,25,26)

HIDE SMILES / InChI

Molecular Formula	C18H15ClN6OS2
Molecular Weight	430.934
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800019470 | https://www.sunesis.com/data-pdf/314/SNS-314_Poster.pdf | https://www.drugbank.ca/drugs/DB06134 | https://www.ncbi.nlm.nih.gov/pubmed/19372566

SNS 314 is a selective small molecule inhibitor of Aurora kinases A, B and C. The compound was being developed by Sunesis Pharmaceuticals for the treatment of cancer. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death. SNS-314 inhibits tumor growth in a variety of preclinical models, and it was being tested in single agent Phase 1 studies in patients with advanced solid tumours.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Aurora kinase A 4 Target ID: O14965 Gene ID: 6790.0 Gene Symbol: AURKA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19649632	Inhibitor 8297	9.0 nM [IC50]
Aurora kinase B 3 Target ID: Q96GD4\|\|\|O60446 Gene ID: 9212.0 Gene Symbol: AURKB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19649632	Inhibitor 8297	31.0 nM [IC50]
Aurora kinase C 2 Target ID: Q9UQB9 Gene ID: 6795.0 Gene Symbol: AURKC Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19649632	Inhibitor 8297	3.4 nM [IC50]
High affinity nerve growth factor receptor 3 Target ID: P04629\|\|\|Q7Z5C3 Gene ID: 4914.0 Gene Symbol: NTRK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19649632	Inhibitor 8297	12.0 nM [IC50]
BDNF/NT-3 growth factors receptor 4 Target ID: Q16620 Gene ID: 4915.0 Gene Symbol: NTRK2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19649632	Inhibitor 8297	5.0 nM [IC50]

PubMed

Title	Date	PubMed
Discovery of a potent and selective aurora kinase inhibitor.	2008 Sep 1	18678489
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.	2010 Mar	19649632
Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.	2017 Apr 25	28427193

Patents

Sample Use Guides

In Vivo Use Guide

Mice: In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 led to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h, indicating effective Aurora-B inhibition in vivo.

Route of Administration: Intraperitoneal

In Vitro Use Guide

SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively and less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:17:25 GMT 2023` Edited by `admin` on `Fri Dec 15 16:17:25 GMT 2023`
Record UNII	802IFJ0Z8X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SNS-314

Common Name

English

UREA, N-(3-CHLOROPHENYL)-N'-(5-(2-(THIENO(3,2-D)PYRIMIDIN-4-YLAMINO)ETHYL)-2-THIAZOLYL)-

Systematic Name

English

SNS 314 [WHO-DD]

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C70655